Aptar Announces CE Marking for LuerVax® and Accompanying Spray Divider, Strengthening Support for Vaccine Developers

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Oct 14, 2026--

Aptar Pharma, part of AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today announced that its LuerVax ® intranasal delivery device and accompanying Spray Divider have been CE marked under the EU Medical Device Regulation (MDR), indicating that they meet the European general safety and performance requirements for medical devices. This milestone expands Aptar Pharma’s support for customers developing innovative intranasal vaccine products.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014098299/en/

LuerVax ® is an intranasal delivery device for administration of vaccines by a healthcare professional, when connected to a compatible LuerLock syringe. The optional Spray Divider is designed to enable the delivery of two sequential sprays, one per nostril. This gives vaccine developers access to a CE-marked intranasal delivery platform, to support development activities from early clinical studies through commercialization.

The CE marking demonstrates Aptar Pharma's continued commitment to delivering high-quality, compliant device solutions designed to help customers throughout vaccine development.

“Achieving CE marking for both LuerVax ® and the Spray Divider is an important step in strengthening our support of vaccine developers worldwide,” said Alex Theodorakis, President, Aptar Pharma Prescription. “Customers are increasingly seeking established device platforms that can support regulatory pathways and enable efficient clinical and commercial development. This CE marking reinforces Aptar's commitment to being a trusted partner throughout the vaccine development journey.”

Supporting Customers from Clinical Development to Commercialization

LuerVax ® and Spray Divider provide a flexible and reliable intranasal delivery platform intended to support a broad range of vaccine development programs.

Spray Divider is available in two sizes, 200 µL and 500 µL, for use with the corresponding LuerLock syringe, designed to enable the prepared syringe volume to be delivered as two sequential sprays, one per nostril.

Beyond access to a CE-marked intranasal delivery platform, customers can leverage Aptar Pharma's expertise in drug delivery, vaccine technologies, regulatory support, industrialization and manufacturing. This integrated approach helps vaccine developers navigate development activities from early clinical studies through commercialization while benefiting from a single partner that can support key stages of the development journey.

Advancing Intranasal Vaccine Delivery

As interest in non-invasive vaccine administration continues to grow, intranasal delivery offers the potential to improve patient acceptance and ease of administration while supporting innovative immunization strategies. With the CE marking of LuerVax ® and the Spray Divider, Aptar is well positioned to help customers capitalize on these opportunities through delivery technologies and development expertise.

"This achievement reflects Aptar's ongoing investment in innovative delivery solutions that address the evolving needs of vaccine developers," said Nektaria Karavas, Global Business Development Director - Vaccines and Antivirals, Aptar Pharma. "Our goal is to provide customers with the delivery technologies, expertise and regulatory support to bring the next generation of vaccines to market."

Regulatory Information

LuerVax ® is a Class I non-sterile, single use medical device under MDR intended for use by healthcare professionals, validated with compatible LuerLock syringe. The Spray Divider is an optional component intended to be used with LuerVax ® and the corresponding LuerLock syringe Refer to the Instructions for Use for the full intended use, warnings and precautions. LuerVax ® is a registered trademark of AptarGroup, Inc. or its affiliates.

About Aptar Pharma

Aptar Pharma is part of AptarGroup, Inc., a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing. Aptar partners with the world’s top healthcare and consumer brands to deliver medicines and create exceptional user experiences. Serving diverse markets, from pharmaceutical to beauty to food and beverage, Aptar combines expertise with proprietary design, engineering and science to develop innovative solutions that help improve lives worldwide. Headquartered in Crystal Lake, Illinois, Aptar employs 14,000 dedicated people across 20 countries. For more information, visit www.aptar.com.

This press release contains forward-looking statements, including regarding the use of Aptar’s LuerVax ® intranasal delivery device and Spray Divider in vaccine development and commercialization, growth in intranasal vaccine delivery, and Aptar’s positioning and goals with respect to these opportunities. Forward-looking statements generally can be identified by the fact that they do not relate strictly to historical or current facts and by use of words such as “expects,” “anticipates,” “believes,” “estimates,” “future,” “potential,” “continues,” “goal,” “positioned” and other similar expressions or future or conditional verbs such as “will,” “should,” “would” and “could.” Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs as well as assumptions made by and information currently available to us. Accordingly, our actual results or other events may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment including, but not limited to: risks that vaccine developers may not adopt LuerVax ® or the Spray Divider for their programs; risks that the devices may not be compatible with, or perform as intended with, particular vaccine formulations; risks related to clinical development activities and regulatory approvals of vaccine candidates, which are conducted and obtained by third parties; risks related to maintaining CE marking and compliance with the EU Medical Device Regulation and other regulatory requirements; development, commercialization, manufacturing and supply risks; and competition, including technological advances. For additional information on these and other risks and uncertainties, please see our filings with the Securities and Exchange Commission, including the discussion under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Form 10-K and Form 10-Qs. We undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Aptar Announces CE marking for LuerVax® and Accompanying Spray Divider

HOUSTON (AP) — A U.S. Immigration and Customs Enforcement officer appeared to intentionally drive a vehicle into a Mexican construction worker in Houston then fled the scene, a prosecutor said Wednesday, rejecting the agency’s claim the man stepped in front of the vehicle while running from authorities.

A family member of Miguel Parra Hernandez, 48, also disputed the identity of a man who ICE says was with him and had been the target of Saturday’s operation, saying they had never seen or heard of that person before.

Both called into question the details provided by ICE surrounding the encounter that has added fuel to fiery criticism of immigration enforcement operations in Houston, where local prosecutors are already investigating a July fatal shooting by a federal immigration officer.

Surveillance footage shows a black SUV speeding over a median and driving toward a man who is running away. The video does not show the car hitting him — that view is blocked by another vehicle — but it shows the SUV inches from the fleeing man. The video then shows him on the ground.

Harris County District Attorney Sean Teare, a Democrat, told The Associated Press the video clearly shows Mr. Parra running away from the unmarked vehicle driven by an ICE officer. The agency has claimed Parra Hernandez ran in front of it.

“That vehicle jumped a median, drove into a parking lot and drove directly at and then over Mr. Parra,” Teare said.

Parra Hernandez underwent surgery for a broken leg later Saturday and also needs surgery on his ankle, his lawyer, Kim Bruno, said during a news conference Wednesday. He remains in ICE custody in the hospital, she said.

Teare said ICE already had two detainees in the SUV — a Jeep Cherokee — when it ran over Parra Hernandez, and his office will get statements from both of them before making a charging decision, likely next week.

His office spoke with Parra Hernandez on Tuesday in the hospital.

“What I’ve seen so far indicates to me that this agent intentionally struck this person and ran him over,” Teare said.

After Parra Hernandez was hit, the Harris County Sheriff's office and the Harris County District Attorney's office went to the scene with a tow truck to impound the ICE vehicle and download crash data, Teare said.

But the same ICE officer who drove the vehicle into Parra Hernandez had fled the scene in the SUV, thus keeping the vehicle in ICE's possession, Teare said. Driving a vehicle that has been involved in a collision writes over or erases the data recorded by the vehicle, he said.

“Any law enforcement officer knows those facts. ICE, either intentionally or through gross negligence, destroyed potential evidence in this case,” Teare said.

Teare said his office is evaluating several possible charges to bring against the ICE officer, including assault with a deadly weapon.

Allegations that officers intentionally struck Parra Hernandez are “reckless” and “false,” ICE said in a statement. Parra Hernandez had been in a vehicle with the target of an enforcement operation, and when officers tried to stop the car, the two men fled on foot, the agency said.

He “ran in front of an ICE vehicle and was struck,” ICE said.

Cesar Espinosa, executive director of FIEL Houston, an immigrant rights organization, flatly denied this claim during a news conference Wednesday, citing the surveillance video.

Attorneys and relatives of others who were arrested by ICE during the operation Saturday denied during the news conference that the man ICE named as the target of its operation — Jose Mendoza-Cervantes — was even in the white van, saying they didn’t know anyone of that name.

Espinosa said Parra Hernandez comes from Mexico and has been in the U.S. for 34 years. He declined to share Parra Hernandez’s status, but said he is living in the U.S. without authorization.

He said two ICE officers were in the room when he visited Parra Hernandez at the hospital.

Teare said ICE and the Department of Homeland Security have not cooperated with his office during its investigation.

In July, Teare said DHS also ignored his request for information after an ICE officer fatally shot 52-year-old Lorenzo Salgado Araujo. The shooting was one of at least 10 deaths involving encounters with immigration officers since the start of President Donald Trump’s mass deportation campaign.

Wilder is a corps member for The Associated Press/Report for America Statehouse News Initiative. Report for America is a nonprofit national service program that places journalists in local newsrooms to report on undercovered issues.

Attorney Kim Bruno speaks about an Immigration and Customs Enforcement action involving Miguel Parra Hernandez, during a news conference, Wednesday, Oct. 14, 2026, in Houston. (Raquel Natalicchio/Houston Chronicle via AP)

Cesar Espinosa of FIEL speaks during a news conference about an Immigration and Customs Enforcement action involving Miguel Parra Hernandez, during a news conference, Wednesday, Oct. 14, 2026, in Houston. (Raquel Natalicchio/Houston Chronicle via AP)

Rodolfo Parra, brother of Miguel Parra-Hernandez, speaks to the media Monday, Oct. 12, 2026, alongside Cesar Espinosa, executive director of FIEL, near the scene on Clay Road near Texas 6 in Houston where Parra-Hernandez was struck by ICE agents after running from an SUV pursuing another man. (Jill Karnicki/Houston Chronicle via AP)

Harris County Sheriff deputies work the scene after a man was struck by an ICE agent's vehicle during an immigration enforcement in northwest Houston, Saturday, Oct. 10, 2026. 9Jason Fochtman/Houston Chronicle via AP)

Sarah Fischer, a local artist who collaborates with Fiel to provide emergency portraiture, holds her artwork of Miguel Parra-Hernandez, during a press conference Monday, Oct. 12, 2026, near the scene on Clay Road near Texas 6 in Houston where Parra-Hernandez was struck by ICE agents after running from an SUV pursuing another man. (Jill Karnicki/Houston Chronicle via AP)

People watch as Harris County Sheriff deputies work the scene near two vehicles involved after a man was struck by an ICE agent's vehicle during an immigration enforcement operation in northwest Houston, Saturday, Oct. 10, 2026. 9Jason Fochtman/Houston Chronicle via AP)